-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Pharmaceutical receives USD 30 million upfront payment from AstraZeneca under siRNA pact

PUBT·08/12/2026 12:19:00
Listen to the news
CSPC Pharmaceutical receives USD 30 million upfront payment from AstraZeneca under siRNA pact
  • CSPC received a USD 30 million upfront payment from AstraZeneca on Aug. 12 under an siRNA collaboration, option, and license deal.
  • Funding supports development of small nucleic acid drug candidates using CSPC’s proprietary siRNA discovery platform with extrahepatic targeted delivery technology.
  • Payment follows the agreement announced on July 2, 2026, signaling continued progress in the strategic R&D collaboration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260812-12281869), on August 12, 2026, and is solely responsible for the information contained therein.